1. Fuster V, Rydén LE, Cannom DS, et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society, ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—executive summary : A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48: 854-906.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults National Implications for Rhythm Management and Stroke Prevention: the Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
3. Henninger N, Goddeau RP Jr, Karmarkar A, et al. Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes. Stroke 2016; 47: 1486–1492.
4. Freedman B. Major progress in anticoagulant uptake for atrial fibrillation at last: does it translate into stroke prevention. European Heart Journal 2018; 39: 2984–2986.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial ﬁbrillation. Ann Intern Med 2007; 146: 857–867.
6. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013; 35(3): 333-335.
7. P.B. Persson, P. Hansell, P. Liss. Pathophysiology of contrast medium–induced nephropathy, Kidney Int. 2005; 68: 14–22.
8. S. Heptinstall, A. White, N. Edwards, J. Pascoe. Differential effects of three radiographic contrast media on platelet aggregation and degranulation: implications for clinical practice? Br J Haematol. 1998; 103: 1020–1030.
9. Laura G. Melton, Gregory J. Dehmer, David A. Tate, et al. Variable Influence Of Heparin and Contrast Agents On Platelet Function As Assessed By The In Vitro Bleeding Time. Thrombosis Research 1996; Vol.83 No.3: 265-277.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group 2016 ESC Guidelines for the management of atrial fibrillition developed in collaboration with EACTS . European Heart Journal 2016; 37: 2893–2962.
12. Raskob GE, Angchaisuksiri P, Blanco AN, et al. ISTH Steering Committee for World Thrombosis Day, Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34: 2363-2371.
13. Uğuz B, Ari S, Çamci S, Ari H. In vitro analysis of the effect of contrast agents on the antiaggregant effects of P2Y12 inhibitors. Thrombosis Research 2019; 183: 91–97.
14. Frohlich J. Systematic survey of interactions between contrast media and other drugs. Special edition by Guerbet Switzerland 2001.
15. Massee DR, Smith DC, Westengard JC, Bull BS. Heparin supplementation of nonionic contrast agents, Journal of Vascular and Interventional Radiology 1991; 2: 209-213.
16. Parvez Z, Moncada R, Messmore H, Fareed J. Ionic and non-ionic contrast media interaction with anticoagulant drugs, Acta Radiologica Diagnosis 1982; 23: 401-404.
17. McCullough P.A, Choi J.P, Feghali G.A, et al. Contrast-Induced Acute Kidney Injury. Journal of the American College of Cardiology 2016; 68 (13): 1465-1473.
18. Akrawinthawong K, Ricci J, Cannon L, et al. Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrastinduced nephropathy (ENCINO), a prospective study Ren Fail 2015; 37: 187–191.
19. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-1507.
20. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50(7): 743-753.
21. Pokorney SD, RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation - RENAL-AF. At the American Heart Association Annual Scientific Sessions (AHA 2019), Philadelphia, PA, 2019;November 16.
22. Kuno T, Takagi H, Ando T, et al. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis J Am Coll Cardiol. 2020; 28;75(3): 273-285.
23. Sikorska J and Uprichard J, Direct Oral Anticoagulants: A Quick Guide. European Cardiology Review 2017; 12(1): 40–45.
24. Cuker A, Siegal DM, Crowther MA, Garcia DA, Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants. J Am Coll Cardiol 2014; 64: 1128–1139.
25. Kitchen S, Gray E, Mackie I, on behalf of the BCSH committee, Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. British Journal of Haematology. 2014;166: 830–841.
26. Kilinc Y, Şasmaz I, Bozkurt A, et al, Effect of the Radiographic Contrast Material Iopamidol on Hemostasis: An Observational Study in Thirty Cardiac Patients. Curr Ther Res Clin Exp 2003; 64: 461–472.
27. Hoffmann JJ, Tielbeek AV, Krause W. Haemostatic effects of low osmolar non-ionic and ionic contrast media: a double-blind comparative study. Br J Radiol 2000; 73(867): 248-255.
28. Margetić S, Ćelap I, Brkljačić DD, et al. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations. Biochem Med (Zagreb). 2020; 15; 30 (1) : 010702.
29. Gosselin RC, Francart SJ, Hawes EM, et al. Annals of Pharmacotherapy. 2015, Vol. 49(7) 777–783.